Skip to content
CELLECT Laboratories logo

About us

CELLECT is revolutionizing women’s health diagnostics with a non-invasive, accessible, and cost-effective solution. Using patented nanotechnology, CELLECT’s innovative collection device is embedded in menstrual products, capturing and stabilizing cervical cells and DNA directly from menstrual blood. This groundbreaking approach eliminates the need for invasive procedures like Pap smears, overcoming barriers of accessibility, affordability, and cultural stigma that hinder traditional screening methods.

Targeting HPV and cervical cancer diagnostics as a starting point, CELLECT’s technology is designed to integrate seamlessly with existing gold-standard laboratory testing. Beyond cervical cancer, CELLECT’s platform has the potential to expand into diagnostics for other reproductive health conditions, such as endometriosis and STIs, as well as leveraging vaginal fluids for further R&D applications.

Program engagement

CELLECT Laboratories Inc.

Leadership

Ibukun Elebute

Co-Founder & COO

CT Murphy

Co-Founder & CEO

Status

Intellectual Property

Fundraising

Sector

Subsector

Our website uses cookies to ensure you get the best experience. Learn more about the policy

i.d.e.a. Fund Applications Open

Applications are now open for i.d.e.a. Fund Cohort 4

Are you developing and/or redesigning new green products, services, processes, and technologies that reduce environmental impact?

The i.d.e.a.™ Fund program focuses on supporting a more sustainable economy while fostering an inclusive and equitable growth in southern Ontario. Find out if you’re eligible to access up to $20,000 in matching seed funding and 30 hours of expert mentorship.

Applications are open from June 16 to July 7, 2025.